Th17细胞因子IL-17A与乙肝疫苗无/弱应答关联的研究

Study on the relationship between Th17 cytokine IL-17A and non-response or poor immune response to HBV vaccine

目的了解Th17细胞因子IL-17A水平与乙肝疫苗免疫无/弱应答发生的关联。方法在1 481名完成乙肝疫苗全程接种的年轻成人中筛选出无/弱应答者30人,根据无/弱应答者性别、年龄和BMI,分别选择抗-HBs抗体中滴度、高滴度正常应答者各30例与之匹配形成对照,检测、比较三组人群血清中IL-17A的浓度差异。并检测无/弱应答者,加强接种1剂次60μg乙肝疫苗后血清IL-17A变化情况。结果 IL-17A在无/弱应答组血清水平中位数为225.16pg/ml(QIR:176.91,287.13),中滴度组为237.37pg/ml(QIR:164.09,266.68),高滴度组为219.05pg/ml(QIR:194.62,261.82),三组间差异无统计学意义(x^2=0.072,P=0.965);无/弱应答组在加强一剂次后IL-17A浓度为241.64pg/ml(QIR:222.40,241.64),高于加强前水平,但差异无统计学意义(Z=-1.175,P=0.240)。结论本研究未能证明Th17细胞因子IL-17A与乙肝疫苗接种无/弱反应发生存在关联。

Objective To understand the association between Th17 cytokine interleukin-17A （IL-17A） expression and non -response or poor immune response to HBV vaccine.Methods We screened out 30 non-responders or poor responders among 1,481 young adults who had received a full course of HBV vaccination.Based on the gender,age and BMI of the nonresponders and poor responders,normal responders with medium anti-HBs geometric mean titer （GMT） （n =30） and those with high anti-HBs GMT （n =30） were matched as the controls.The serum IL-17A concentration was detected and compared among the three groups.Besides,all of the non-responders and poor responders were detected for the changes of serum IL -17A concentration after a looster of 60μg hepatitis B vaccine.Results The medium values of serum IL-17A in the non-or poor-response group,medium anti-Hts GMT group and high anti-HBs GMT group were 225.16 pg/ml （QIR：176.91,287.13）,237.37 pg/ml （QIR：164.09,266.68） and 219.05 pg/ml （QIR：194.62,261.82）,respectively,and no statistically significant difference was found among the three groups （x2 =0.072,P =0.965）.After receiving the booster,the concentration of IL-17A in the non-or poor-response group was 241.64 pg/ml （QIR：222.40,241.64）,which was higher than that before the booster,but no statistically significant difference was found （Z =1.175,P =0.240）.Conclusions This research fails to demonstrate that Th17 cytokine IL-17A has a connection with non-response or poor immune response to HBV vaccine.